Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 475-477

  Sachse, M M ^a   Wagner, G ^a  

^a General Hospital of Bremerhaven Reinkenheide   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOREARM; HUMANS; INDOLES; KERATOACANTHOMA; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; RETINOIDS; SKIN NEOPLASMS; SULFONAMIDES; TRETINOIN;

EID: 84894252855     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12659     Document Type: Letter

References (13)

1. Anforth R, Blumetti TC, Mohd Affandi A, Fernandez-Peñas P,. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012; 30: e165-7.
2. Anforth R, Fernandez-Peñas P, Long GV,. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: e11-18.
3. Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
4. Ormerod AD, Campalani E, Goodfield MJ, BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-63.
5. Shaw JC, White CR Jr,. Treatment of multiple keratoacanthomas with oral isotretinoin. J Am Acad Dermatol 1986; 15: 1079-82.
6. Mensing H, Wagner G,. Solitary keratoacanthoma treated with etretinate. Z Hautkr 1988; 63: 234-6.
7. Marquez CB, Smithberger EE, Bair SM, et al,. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control 2009; 16: 66-9.
8. Oberholzer PA, Kee D, Dziunycz P, et al,. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
9. Lacouture ME, Chapman PB, Ribas A, et al,. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol (Meeting Abstracts) 2011; 29 (Suppl. 1): 8520.
10. Lacouture ME, O'Reilly K, Rosen N, Solit DB,. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 2012; 30: 329-30.
11. Crowe DL, Kim R, Chandraratna RA,. Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway. Mol Cancer Res 2003; 1: 532-40.
12. Leverkus M,. Malignant epithelial tumors: part I. Pathophysiology and clinical features. J Dtsch Dermatol Ges 2012; 10: 457-71.
13. Carlino MS, Gowrishankar K, Saunders CA, et al,. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013; 12: 1332-42.